DUBLIN--(BUSINESS WIRE)--The "Somatostatin Receptor Type 4 (SSTR4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules.
The latest report Somatostatin Receptor Type 4 - Drugs In Development, 2021, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Metabolic Disorders and Oncology which include indications Acromegaly, Diabetic Neuropathic Pain, Low Back Pain, Neuroendocrine Tumors, Osteoarthritis Pain, Pain and Pituitary ACTH Hypersecretion (Cushing Disease).
Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
- The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics
Key Topics Covered:
Introduction
- Report Coverage
Somatostatin Receptor Type 4 (SSTR4) - Overview
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
- Eli Lilly and Co
- GlyTech Inc
- Peptide Logic LLC
- Strongbridge Biopharma plc
Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles
GT-02037- - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
LY-3556050 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Monoclonal Antibody Conjugate to Agonize SSTR4 for Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
veldoreotide ER - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
veldoreotide IR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Somatostatin Receptor Type 4 (SSTR4) - Dormant Products
Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones
Featured News & Press Releases
- Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290
- May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
- Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
- Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo's Somatoprim
- Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers
- Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly
- Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim
- Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim
- Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients
- Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim
- Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5
- Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim
Appendix
Companies Mentioned
- Eli Lilly and Co
- GlyTech Inc
- Peptide Logic LLC
- Strongbridge Biopharma plc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vgvjal
